slides · global inventory
Evidence
Beat collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 40,452
Current window 25,051-25,080
Pages 1,349
Rows per page 30
Beat
25,051-25,080 of 40,452
08
Includes a cartoon liver character, likely representing the target organ or safety profile.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
10
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
11
Includes detailed source citations in the footer; uses a color-coded legend for different drug treatments.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
12
The slide uses a two-column layout to separate milestones by drug candidate.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
14
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
15
The slide uses a table structure to contrast clinical outcomes across three key value pillars: response rates, tolerability, and outpatient feasibility.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
16
Includes comparative data points for transduction efficiency and experimental data for tonic signaling and anti-exhaustion.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
17
Includes a comparative table of clinical outcomes (ORR/CR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
18
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
19
The slide uses a two-column layout to contrast clinical results for Multiple Myeloma vs. AL Amyloidosis, supported by market data for existing therapies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
21
The slide uses a red dashed box to highlight the core clinical data rows for comparison.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
06
The slide explicitly notes that these are cross-trial comparisons and not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
07
The slide uses a table structure to contrast standard of care with the company's target segment. The bottom section uses bar charts to imply relative patient population growth.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
08
The slide explicitly warns about cross-trial comparison limitations in the footer.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem1 hit
45
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Team1 hit
46
The slide is divided into two sections: ImmixBio Clinical Advisory Board (top) and Select Nexcella Scientific Advisory Board Members (bottom).Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Team1 hit
47
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Team1 hit
48
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Team1 hit
09
This is a stylistic section divider slide with an abstract background.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
10
The slide uses a biological pathway diagram to illustrate the mechanism of action and a callout box for the therapeutic thesis.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
11
The slide uses a combination of a biological mechanism diagram, a market data table, and a callout box for competitive limitations.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
12
The slide uses a side-by-side comparison framework to contrast healthy volunteer data with patient data.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
13
The slide uses a bulleted list structure to categorize findings between healthy volunteers and patients, concluding with a strategic partnership milestone.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
14
Clinical trial baseline data table.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
15
The slide provides a breakdown of patient outcomes including completion and withdrawal reasons.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
16
HS = Hidradenitis Suppurativa, AD = Atopic Dermatitis, HV = Healthy Volunteers, PK = Pharmacokinetics, PD = Pharmacodynamics, MS = Mass Spectrometry, LLOQ = Lower Limit of Quantitation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit
17
The chart demonstrates therapeutic efficacy by showing post-treatment levels (Day 28) dropping below or equal to the healthy subject baseline.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations Beat · Desire1 hit